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Duchenne muscular dystrophy (DMD) is a lethal X-linked disorder caused by mutations in the 
dystrophin gene. It is the most common and severe form of muscular dystrophy, affecting 
approximately one in 3500 boys at birth worldwide. 
Multiple strategies have been proposed to replace functional dystrophin in individuals suffering from 
DMD, including muscle stem cell transplants to engraft healthy donor muscle cells or gene therapy 
to stimulate exogenous dystrophin expression in affected tissues. Researchers including Drs. Zejing 
Wang, Dusty Miller, Rainer Storb and Stephen Tapscott in the Human Biology and Clinical Research 
divisions, in collaboration with Dr. Jeffrey Chamberlain from the University of Washington, are 
actively pursuing these approaches. 
Adeno-associated virus (AAV) has been extensively used as a gene delivery agent for gene therapy 
because most of its genome can be replaced with therapeutic genes, and such genes can be 
expressed for long periods without integration into the host genome. In addition, AAV is non-
pathogenic to humans and animals and infects replicating and non-replicating cells alike. Despite 
these advantages, however, initial attempts to treat DMD by AAV-mediated dystrophin gene delivery 
have failed. This has been attributed in part to host immune responses to AAV and/or its gene 
products, given the observed accumulation of T cell infiltrates at the sites of intramuscular AAV 
administration. 
Therefore, to improve gene delivery by preventing unwanted host immune responses to AAV-
dystrophin, Wang and colleagues previously evaluated the levels of dystrophin expression following 
combined immunosuppression and gene therapies in a canine model of DMD (Wang et al. Molecular 
Therapy 2007). 
The authors were the first to demonstrate that a triple-drug cocktail can partially restore dystrophin 
levels out to 30 weeks post-AAV therapy (12 weeks after cessation of immunosuppression). This 
immunosuppression regimen included anti-thymocyte globulin (ATG), a T cell depletion agent, and 
the T cell inhibitors cyclosporine (CSP) and mycophenolate mofetil (MMF) – all of which are routinely 
used for bone marrow and solid organ transplants. 
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In their most recent study, Wang and colleagues evaluated this immunosuppression regimen for a 
longer duration (24 weeks versus 18 in the previous study) with a large scale infusion of higher does 
of the AAV-dystrophin vector into a group of muscles in the hind limbs of two DMD-affected animals. 
Remarkably, in the treated limb of one individual they found near uniform dystrophin expression by 
immunohistochemical staining two years after gene therapy and 18 months after 
immunosuppression. In contrast, dystrophin expression was not observed in the contralateral control 
limb that did not receive gene therapy. Moreover, the muscle histology of the treated limb was 
significantly improved with no obvious T cell infiltrates observed in the earlier or later biopsies. In the 
second individual, dystrophin expression was less uniform, but still stable, in the treated limb out to 
19 months. Interestingly, only this individual possessed readily detectable serum neutralizing 
antibodies against AAV prior to gene therapy, whereas both individuals developed peak AAV-
neutralizing antibody responses to AAV following AAV-dystrophin delivery. 
These provocative results demonstrate that combining transient immunosuppression with gene 
therapy could provide unprecedented treatment efficacies for DMD. It also suggests that the success 
of these treatments will depend on the level of pre-existing immunity to AAV or other gene delivery 
vectors. 
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Left two panels show a biopsy from the 
treated limb of an individual with DMD 
exhibiting nearly uniform dystrophin 
expression following combined 
immunosuppression and gene therapy. 
Right two panels show a biopsy from the 
contralateral control limb in the same 
individual, which did not receive gene 
therapy. Top and bottom panels show: A) 
immunohistochemical staining of 
dystrophin, where inset shows a healthy 
animal control without DMD, and B) 
hematoxylin and eosin staining of nuclei 
and cell cytoplasm, respectively. Bar 
represents 100 micrometers. 
